ClinicalTrials.gg
Not yet recruitingNCT07939516IGNITIONUpdated Nov 16, 2026

Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome

A Phase 4 interventional study of Genotype guided P2Y12 therapy and Standard therapy group in Acute Coronary Syndromes (ACS), Unstable Angina Pectoris and Myocardial Infarction (MI), sponsored by Medisch Spectrum Twente. Not yet recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Medisch Spectrum Twente · Phase 4, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies in Acute Coronary Syndrome with a site in Netherlands — 15 open to participants now, 17 under way, none of them phase 3. Acute Coronary Syndrome · Netherlands.

Planned enrollment
23rd of 66
3,120 · median 1,811
Started
2026
with 3 others
Phase 4
11 of 86
5 open now
Primary completion
2029-11
later than 13 of 16 live
Registered
85th of 86
by date

Among the 86 studies in Acute Coronary Syndrome with a site in Netherlands, this one is the 23rd largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2026, is one of 11 in phase 4, reaches primary completion later than 13 of the 16 other live ones, and was the 85th registered.

Acute Coronary Syndrome

1,490 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

15 of the 86 studies in Acute Coronary Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Acute Coronary Syndrome with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.

Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form.

Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers.

Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice.

Participants will receive:

  1. Standard treatment at the discretion of the cardiologist, or
  2. Genotype-guided treatment (based on the presence of a LOF allele)

Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started.

Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.

Read the detailed description

Rationale Patients diagnosed with acute coronary syndrome (ACS) require dual antiplatelet therapy (DAPT) for 12 months. This typically includes aspirin and a P2Y12 inhibitor. Irrespective of the treatment strategy (i.e., invasive or conservative), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events.

Although ischemic complications usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. Yet, in 30% of the (white) European patients are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate metabolization of clopidogrel.

Despite knowledge of these loss of function mutations, current ACS guidelines do not provide specific recommendations on individualized, genotype-based treatment with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as the conucted trials were underpowered due to sample size calculations based on ischemic endpoints, and the exclusion of ACS patients with high-risk features.

Objective

This randomized clinical trial aims to investigate whether individualized genotype-guided DAPT is non-inferior at 18 months follow-up to standard clinical practice of DAPT in all-comer patients with ACS with regard to:

  • the primary endpoint of Ischemic Endpoint, a composite of cardiovascular death, myocardial infarction, or ischemic stroke, and
  • the co-primary endpoint of Net Adverse Cardiovascular Events (NACE), a composite of major bleeding, cardiovascular death, myocardial infarction, or any stroke.

Trial design This is a randomized, investigator-initiated, multicentre trial with 1:1 randomization of all-comer ACS patients for genotype-guided antiplatelet therapy, stratified for the presence of diabetes mellitus, sex and PCI.

Trial population All patients of 18 years or older with ACS, irrespective of the treatment strategy. If patients did not undergo a coronary angiography, there must be a history of coronary artery disease, proven myocardial defect by cardiac imaging that matches with previous MI, proven myocardial ischemia, or a known coronary obstruction ≥30% as previously visualized.

Interventions

If no major events (defined by NACE) occur during the first 30 days, patients will be randomly assigned (1:1) to:

  1. Standard treatment at the discretion of the cardiologist, or
  2. Genotype-guided treatment (based on CYP2C19 loss of function alleles) Patients included in the genotype-guided group who do not carry a LOF allele will be classified as normal or ultrafast metabolizers, and will de-escalate after 30 days from standard therapy (with ticagrelor or prasugrel) to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started. If the test results are inconclusive, de-escalation will be carried out.

Ethical considerations As both treatment strategies (i.e. aspirin plus clopidogrel or ticagrelor or prasugrel) are commonly used in treatment of ACS and considered standard care in Europe according to the ESC guidelines, no risks will be attached to treatment with any of the P2Y12 inhibitors. Patients who receive an individualized treatment strategy will possibly benefit from this, due to lower risk of bleeding complications.

03

Conditions studied

  • Acute Coronary Syndromes (ACS)
  • Unstable Angina Pectoris
  • Myocardial Infarction (MI)
  • STEMI
  • NSTEMI

Keywords

  • acute coronary syndrome
  • dual antiplatelet therapy
  • genotyping
  • P2Y12 inhibitor
  • clopidogrel
  • ticagrelor
  • bleeding event
  • ischemic event
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of 18 years and older, who are capable of providing and were diag-nosed with an acute coronary syndrome
  • Patients with a coronary angiography showing obstructive coronary artery disease at time of di-agnosis (or up to 30 days thereafter)
  • Patients in whom no coronary angiography is performed during the index hospitalization or the first 30 days after the ACS, need to have at least one of the following:

    • known history of coronary artery disease (i.e., a previous MI, PCI, or coronary artery bypass grafting (CABG)),
    • proven myocardial defect by cardiac imaging that matches with previous MI,
    • proven myocardial ischemia, or
    • known coronary artery atherosclerosis as previously visualized.

Exclusion criteria

Exclusion Criteria:

  • Known intolerance to or absolute for clopidogrel, ticagrelor, prasugrel or acetyl-salicylic acid.
  • Use of oral anticoagulant therapy.
  • Contra-indication for standard treatment with ticagrelor.
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or lap-aroscopic) within the past 6 months prior to randomization or any major surgical procedure planned 6 months after randomization.
  • Participation in another randomized cardiovascular device trial or randomized pharmacological trial related to antithrombotic and/or anticoagulant therapy before reaching the primary end-point.
  • Known pregnancy, adherence to scheduled follow-up is unlikely, or is assumed to be less than 18 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,120 participants (estimated)

Study arms

  • Active comparator
    Standard therapy

    Dual antiplatelet therapy described at the cardiologist's discretion

    Drug: Standard therapy group

  • Experimental
    Genotype based therapy

    Dual antiplatelet therapy based on CYP2C19 genotype. In case of normal or ultrafast metabolizer, patient will receive Clopidogrel 30-days after acute coronary syndrome. In case of proven carrier of the loss-of-function allele, patient will continue with ticagrelor.

    Drug: Genotype guided P2Y12 therapy

Interventions

  • DrugGenotype guided P2Y12 therapy

    All patients with ACS can be enrolled. Randomization will take place at time of ACS diagnosis. For the first 30 days after the index event, patients will be treated with DAPT as prescribed by the cardiologist. Patients who experience a major event (any death, spontaneous MI, definite stent thrombosis, any stroke, and major bleeding) during the first 30 days will be excluded from the main analysis. For these patients, DAPT treatment will remain unchanged. Included patients will be randomly assigned (1:1) to: 1. Standard treatment at the discretion of the cardiologist 2. Genotype-guided treatment In the patients randomized to the intervention arm genotyping will be performed and patients who do not carry a LOF allele will be classified as normal or ultrafast metabolizers. In these patients, de-escalation of P2Y12 inhibitor from standard therapy to clopidogrel will be performed around 30 days. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place.

  • DrugStandard therapy group

    Patients randomized for the standard therapy arm will receive dual antiplatelet therapy at the descretion of the cardiologist

06

What researchers measure

Primary outcomes

  1. Ischemic endpoint

    Composition of cardiovascular death, myocardial infarction, definite stent thrombosis and ischemic stroke

    Time frame: At 18 months follow-up

  2. Net Adverse Cardiovascular Events

    Composition of cardiovascular death, major bleeding, myocardial infarction, definite or probable stent thrombosis, and any stroke

    Time frame: At 18 months follow-up

Secondary outcomes

  1. Adverse events

    Death, Myocardial infarction, repeat revascularization, stroke, stent thrombosis, and bleeding

    Time frame: At 18 months follow-up

  2. Patient reported chest pain

    Severity of chest pain by the Canadian Cardiovascular Society Angina Grade score classified into four classes (I to IV) based on the amount of exertion that triggers the symptoms. The higher the class, the lower the exercise tolerance.

    Time frame: At 12- and 18-months follow-up

  3. Patient reported dyspnea score

    Prevalance and impact of dyspnea on patient's daily activities classified by the Medical Research Council Dyspnea Scale. There are 5 grades (0 to 4). The higher the grade, the greater the impact.

    Time frame: At 12- and 18-months follow-up

  4. Cost effectiveness analysis between the two treatment groups

    Compare healthcare costs and health outcomes of the two treatment arms. Healthcare costs are determined by extracting healthcare utilization data from electronic health records and multiplying these resource-use frequencies by their corresponding standard unit costs in euros. Health outcomes will be evaluated by assessing patient-reported quality of life through the validated questionnaires EuroQol 5 Dimensions (EQ5D). Quality adjusted life years (QALYs) will be derived from the EQ5D outcomes. Costs per QALY will be compared per treatment arm to compare cost-effectiveness.

    Time frame: At 18 months follow-up

  5. Patient reported quality of life

    Measured by the validated questionnaire EuroQol 5 Dimensions (EQ5D). The EQ5D evaluates a patient's health accross five core dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) giving it a score of 1 (no problems) to 5 (extreme problems).

    Time frame: At 30 days, 12- and 18-months follow-up

Other outcomes

  1. Intention to treat analysis without 30-day adverse event exclusion

    The primary and secondary endpoints will be evaluated in all patients who were initially included at time of ACS diagnosis based on their randomized treatment, i.e., independent of adverse events in the first 30 days after ACS diagnosis and irrespective of received treatment.

    Time frame: At 12- and 18-months follow-up

  2. Outcome differences in bleeding events

    To compare bleeding events (%) in both treatment arms.

    Time frame: At 18-months follow-up

  3. Relation between patients ethnic background (self-reported) and clinical presentation

    Does self-defined ethnic background impact the incidence of clinical presentation (STEMI/NSTEMI/unstable angina). For example, is there an association between non-Western European ethnic background and the type of clinical presentation (STEMI/NSTEMI/unstable angina).

    Time frame: At 18-months follow-up

  4. Relation between patients highest obtained education level and clinical outcome

    Is there a negative correlation between the highest obtained educational level and the incidence of the primary and secondary endpoints (%)

    Time frame: At 18-months follow-up

  5. Correlation between Non-enrollers and enrollers

    Clinical outcome (based on primary and secondary endpoints) of patients who were not enrolled vs patients who were enrolled in the study based on data from medical records

    Time frame: 18 months

  6. Outcome differences diabetes mellitus

    Differences in primary and secondary endpoints (%) of diabetic vs non-diabetic participants.

    Time frame: At 18 months follow-up

  7. Outcome differences gender

    Differences in primary and secondary endpoints (%) of male vs female participants.

    Time frame: At 18 months follow-up

  8. Outcome differences elderly

    Differences in primary and secondary endpoints (%) of elderly (\>= 75 years) vs non-elderly participants.

    Time frame: At 18 months follow-up

  9. Outcome differences invasive acute coronary syndrome treatment

    Differences in primary and secondary endpoints (%) of participants treated with percutaneous coronary intervention vs non-invasively-treated.

    Time frame: At 18 months follow-up

  10. Outcome differences multivessel disease

    Differences in primary and secondary endpoints (%) of participants treated with multivessel percutaneous intervention vs non treated with mutlivessel percutaneous intervention.

    Time frame: At 18 months follow-up

  11. Outcome differences acute coronary syndrome type

    Differences in primary and secondary endpoints (%) of participants with acute myocardial infarction vs unstable angina.

    Time frame: At 18 months follow-up

  12. Relation between patients ethnic background (self-reported) and dual antiplatelet use

    Does self-reported ethnic background impact the incidence of dual antiplatelet use (therapy adherence). For example, does non-Western European ethnic background have an association with higher therapy adherence? This will be measured by self-reported adherence and pharmacist's records of dual antiplatelet therapy pick up.

    Time frame: At 18 months

  13. Relation between patients ethnic background (self-reported) and clinical outcome

    Does ethnic background impact the incidence of the clinical outcome (primary and secondary endpoints). For example, is there an association between non-Western European ethnic background and lower rates of the primary or secondary endpoints.

    Time frame: At 18 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 36 months is below that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Nov 16, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Nov 15, 2029
CompletionEst.
Mar 1, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939516
Lead sponsor
Medisch Spectrum Twente
Collaborators
Ziekenhuisgroep Twente
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Nov 15, 2029 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Eline Ploumen, MD, PhD
Contact
e.ploumen@mst.nl
+31(0)53 487 2105
Clemens von Birgelen, MD, Prof. Dr.
principal investigator · Medisch Spectrum Twente
Eline Ploumen, MD, PhD
study director · Medisch Spectrum Twente

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion